Gestodene

Subscribe to Selected New Research on Gestodene

138 relevant articles (2 outcomes, 32 trials/studies) found for this Bio-Agent

Description: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer

Also Known As:

13-ethyl-17-hydroxy-18,19-dinor-17 alpha-pregna-4,15-dien-20-yn-3-one; 17-alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one; Gestoden; Gestodene, ((17alpha)-(+-))-isomer; SH B 3331; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 58

Experts

1.	Herment, Nathalie: 1 article (11/2005)
2.	Trenque, Thierry C: 1 article (11/2005)
3.	Picot, Catherine: 1 article (11/2005)
4.	Trenque-Tessereau, Marie-Gilles B: 1 article (11/2005)
5.	Krŭsteva, : 1 article (01/2003)
6.	Rosenbaum, P: 1 article (12/2001)
7.	Düsterberg, B: 1 article (12/2001)
8.	Wessel, J: 1 article (12/2001)
9.	Ruebig, A: 1 article (12/2001)
10.	Endrikat, J: 1 article (12/2001)

Related Diseases

1.	Metrorrhagia (Spotting) 01/01/1987 - "In the total number of gestodene cycles in studies A and B, there was a 6.9% incidence of spotting, a 0.8% incidence of breakthrough bleeding, and a 0.7% incidence of both spotting and breakthrough bleeding in studies A and B patients taking gestodene" 10/01/1995 - "With respect to cycle control, there is a trend towards a lower incidence of intermenstrual bleeding in the gestodene group" 09/01/1994 - "Gestodene group exhibited significantly better cycle control as evidenced by the lower incidence of breakthrough bleeding and spotting" 10/01/1993 - "On the other hand, breakthrough bleeding occurred less often in women in the gestodene group (19.3% vs. 29.6%)" 01/01/1987 - "Cycle control was better during intake of the gestodene-containing preparation, since spotting occurred less frequently (P less than .05)" Get all the results and reference details, order at left...
2.	Endometriosis (Adenomyosis) 03/01/2008 - "PATIENTS AND METHODS: Endometrial biopsies were taken at the time of laparoscopy in 40 patients with endometriosis, 16 of whom were using an oral contraceptive containing gestodene at the time of laparoscopy" 03/01/2008 - "CONCLUSION: Oral contraceptives containing gestodene are effective in decreasing aromatase expression in the eutopic endometrium of patients with endometriosis." 03/01/2008 - "OBJECTIVE: To determine the effect of oral contraceptives containing gestodene on aromatase expression in the endometrium of patients diagnosed with endometriosis" 10/01/2006 - "PATIENT AND METHODS: This was a retrospective cohort study carried out in paraffin-embedded endometrial tissue obtained from patients with a histological diagnosis of adenomyosis obtained during the proliferative (n = 25) and luteal (n = 10) phases of the menstrual cycle and following the use of continuous oral contraception with gestodene/ethinyl estradiol (n = 7)" 10/01/2006 - "OBJECTIVES: To determine whether aromatase expression in the eutopic endometrium and adenomyotic foci is affected by previous use of oral contraceptives containing gestodene, and to determine whether changes in cyclooxygenase-2 (COX-2) expression occur in adenomyosis during the menstrual cycle" Get all the results and reference details, order at left...
3.	Venous Thromboembolism 11/01/1999 - "The warning issued by the UK Committee on Safety Medicines in October 1995, followed by their 'Dear Doctor' letter of October 18, 1995, that oral contraceptive pills containing gestodene or desogestrel were associated with a higher risk of venous thromboembolism has had a negative impact on public heath" 12/01/1997 - "The British Committee on Safety of Medicines' issuance of a public notice of the existence of an increased risk of venous thromboembolism (VTE) from using third-generation pills containing gestodene or desogestrel fomented considerable controversy in late 1995" 11/08/1996 - "In New Zealand, about 75% of OC users (compared to 50% in the UK) use these new OCs and about 40 of the 50 expected cases of venous thromboembolism in New Zealand pill users per year will occur in women taking OCs containing desogestrel or gestodene." 11/08/1996 - "In 1995, the UK Committee on the Safety of Medicines advised physicians not to prescribe OCs containing desogestrel or gestodene to women with risk factors for venous thromboembolism and recommended that current users should continue with these preparations only if they could not tolerate other OCs" 01/01/1996 - "These data appear to completely contradict the earlier allegation of a differential risk for venous thromboembolism (VTE) between desogestrel- and gestodene-based combined OCs" Get all the results and reference details, order at left...
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/1995 - "The study group included 11 young women with uncomplicated IDDM who were prescribed ethinyl estradiol 30 micrograms and gestodene 75 micrograms" 11/01/1994 - "Study subjects were 13 women with uncomplicated IDDM treated with a monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene for 12 consecutive cycles and 13 women of comparable diabetic status as control" 06/01/1991 - "The authors also have preliminary results of a trial of a low-dose monophasic with ethinyl estradiol and gestodene, showing no adverse effects on glycemic control in IDDM patients" 08/01/1994 - "STUDY DESIGN: Twenty-five women with uncomplicated insulin-dependent diabetes mellitus, allocated to treatment with a monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene (treatment group, n = 12) or with nonhormonal contraception (control group, n = 13), were prospectively followed up for 12 months" 06/01/1995 - "RESEARCH DESIGN AND METHODS--A total of 22 women with IDDM received a monophasic combination of ethinyl estradiol and gestodene for 1 year; 20 women of comparable diabetic status using nonhormonal contraception were selected as control subjects" Get all the results and reference details, order at left...
5.	Thromboembolism 09/01/1992 - "A 1988 study in West Germany suggests, however, that women who use gestodene may be at increased risk of thromboembolism" 09/01/1992 - "It probably will not approve gestodene until the question of apparent excess of thromboembolism is resolved." 01/01/1996 - "The unit has already received audits of the effect of changes concerning the risk of thromboembolism from gestodene and desogestrel containing OCs" 01/01/2002 - "In particular, there is debate surrounding whether desogestrel and gestodene carry a greater risk of thromboembolism than levonorgestrel" 07/01/1996 - "In October, 1995, the United Kingdom Committee on Safety of Medicines recommended that women should use oral contraceptives containing desogestrel or gestodene only if prepared to accept an increased risk of thromboembolism" Get all the results and reference details, order at left...
47 Diseases and 138 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Oral Contraceptives
2.	Aromatase (CYP19)
3.	felbamate (Felbatol)
4.	Desogestrel
5.	Levonorgestrel (Plan B)
6.	Progestins (Progestagens)
7.	Ethinyl Estradiol (Estinyl)
8.	Norethindrone (Norethisterone)
9.	norgestimate
10.	Estradiol (Estrace)
228 Drugs and Important Bio-Agents and 128 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Contraception (Birth Control)
2.	Stents
3.	Drug Prescriptions (Prescription, Drug)
3 Therapies and Procedures and 9 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>